Literature DB >> 33014556

Heterogeneity of circulating tumor cell dissemination and lung metastases in a subcutaneous Lewis lung carcinoma model.

Jessica E Fitzgerald1, Brook K Byrd2, Roshani A Patil1, Rendall R Strawbridge2, Scott C Davis2, Chiara Bellini1, Mark Niedre1.   

Abstract

Subcutaneous (s.c.) tumor models are widely used in pre-clinical cancer metastasis research. Despite this, the dynamics and natural progression of circulating tumor cells (CTCs) and CTC clusters (CTCCs) in peripheral blood are poorly understood in these models. In this work, we used a new technique called 'diffuse in vivo flow cytometry' (DiFC) to study CTC and CTCC dissemination in an s.c. Lewis lung carcinoma (LLC) model in mice. Tumors were grown in the rear flank and we performed DiFC up to 31 days after inoculation. At the study endpoint, lungs were excised and bioluminescence imaging (BLI) was performed to determine the extent of lung metastases. We also used fluorescence macro-cryotome imaging to visualize infiltration and growth of the primary tumor. DiFC revealed significant heterogeneity in CTC and CTCC numbers amongst all mice studied, despite using clonally identical LLC cells and tumor placement. Maximum DiFC count rates corresponded to 0.1 to 14 CTCs per mL of peripheral blood. In general, CTC numbers did not necessarily increase monotonically over time and were poorly correlated with tumor volume. However, there was a good correlation between CTC and CTCC numbers in peripheral blood and lung metastases. We attribute the differences in CTC numbers primarily due to growth patterns of the primary tumor. This study is one of the few reports of CTC shedding dynamics in sub-cutaneous metastasis models and underscores the value of in vivo methods for continuous, non-invasive CTC monitoring.
© 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement.

Entities:  

Year:  2020        PMID: 33014556      PMCID: PMC7510907          DOI: 10.1364/BOE.395289

Source DB:  PubMed          Journal:  Biomed Opt Express        ISSN: 2156-7085            Impact factor:   3.732


  56 in total

1.  Significance of manipulating tumour hypoxia and radiation dose rate in terms of local tumour response and lung metastatic potential, referring to the response of quiescent cell populations.

Authors:  S Masunaga; Y Matsumoto; G Kashino; R Hirayama; Y Liu; H Tanaka; Y Sakurai; M Suzuki; Y Kinashi; A Maruhashi; K Ono
Journal:  Br J Radiol       Date:  2010-09       Impact factor: 3.039

2.  Portable two-color in vivo flow cytometer for real-time detection of fluorescently-labeled circulating cells.

Authors:  Steven Boutrus; Cherry Greiner; Derrick Hwu; Michael Chan; Charlotte Kuperwasser; Charles P Lin; Irene Georgakoudi
Journal:  J Biomed Opt       Date:  2007 Mar-Apr       Impact factor: 3.170

3.  Real-time particle-by-particle detection of erythrocyte-camouflaged microsensor with extended circulation time in the bloodstream.

Authors:  Wenjun Di; Xuefei Tan; Isen Andrew C Calderon; Ashlyn E Neal Reilly; Mark Niedre; Heather A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-04       Impact factor: 11.205

4.  Chemosensitivity of micrometastases and circulating tumor cells to uracil and tegafur as evaluated using LacZ gene-tagged Lewis lung carcinoma cell.

Authors:  H Nakanishi; K Kobayashi; T Nishimura; K Inada; T Tsukamoto; M Tatematsu
Journal:  Cancer Lett       Date:  1999-07-19       Impact factor: 8.679

5.  Monitoring circulating prostate cancer cells by in vivo flow cytometry assesses androgen deprivation therapy on metastasis.

Authors:  Kai Pang; Chengying Xie; Zhangru Yang; Yuanzhen Suo; Xi Zhu; Dan Wei; Xiaofu Weng; Xunbin Wei; Zhengqin Gu
Journal:  Cytometry A       Date:  2018-04-23       Impact factor: 4.355

Review 6.  The biology of circulating tumor cells.

Authors:  K Pantel; M R Speicher
Journal:  Oncogene       Date:  2015-06-08       Impact factor: 9.867

7.  Effects of stress on tumor growth and metastasis in mice bearing Lewis lung carcinoma.

Authors:  T Giraldi; L Perissin; S Zorzet; P Piccini; V Rapozzi
Journal:  Eur J Cancer Clin Oncol       Date:  1989-11

8.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

Review 9.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

10.  Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.

Authors:  Nicola Aceto; Aditya Bardia; David T Miyamoto; Maria C Donaldson; Ben S Wittner; Joel A Spencer; Min Yu; Adam Pely; Amanda Engstrom; Huili Zhu; Brian W Brannigan; Ravi Kapur; Shannon L Stott; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Charles P Lin; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Cell       Date:  2014-08-28       Impact factor: 41.582

View more
  4 in total

1.  Short-Term Circulating Tumor Cell Dynamics in Mouse Xenograft Models and Implications for Liquid Biopsy.

Authors:  Amber L Williams; Jessica E Fitzgerald; Fernando Ivich; Eduardo D Sontag; Mark Niedre
Journal:  Front Oncol       Date:  2020-11-06       Impact factor: 6.244

2.  Signal and measurement considerations for human translation of diffuse in vivo flow cytometry.

Authors:  Fernando Ivich; Joshua Pace; Amber L Williams; Malcolm Shumel; Qianqian Fang; Mark Niedre
Journal:  J Biomed Opt       Date:  2022-06       Impact factor: 3.758

3.  Near-infrared diffuse in vivo flow cytometry.

Authors:  Joshua Pace; Fernando Ivich; Eric Marple; Mark Niedre
Journal:  J Biomed Opt       Date:  2022-09       Impact factor: 3.758

4.  Prevention of Melanoma Extravasation as a New Treatment Option Exemplified by p38/MK2 Inhibition.

Authors:  Peter Petzelbauer
Journal:  Int J Mol Sci       Date:  2020-11-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.